Nishikawa Mikiko, Murakumo Yoshiki, Imai Tsuneo, Kawai Kumi, Nagaya Masahiro, Funahashi Hiroomi, Nakao Akimasa, Takahashi Masahide
Department of Pathology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.
Eur J Hum Genet. 2003 May;11(5):364-8. doi: 10.1038/sj.ejhg.5200971.
Germline mutations in the RET proto-oncogene are responsible for the development of human hereditary diseases, including multiple endocrine neoplasia (MEN) type 2A and 2B, familial medullary thyroid carcinoma (FMTC), and Hirschsprung's disease (HSCR). It has been reported that some families developed both MEN 2A/FMTC and HSCR, in which a mutation in a cysteine residue at codon 609, 618, or 620 in the RET gene was present. Here we report a novel RET mutation detected in a Japanese family with medullary thyroid carcinoma and HSCR. A germline mutation in cysteine 611 of the RET gene was identified in this family, which introduced an amino-acid change from cysteine to serine. By biological and biochemical analyses of mutant RET proteins, we previously predicted the potentiality that amino-acid substitution for cysteine 611 as well as cysteines 609, 618, and 620 would promote the development of MEN 2A/FMTC and HSCR. This clinical case substantiates our suggestion for the mechanism of the development of both the diseases.
RET原癌基因的种系突变是人类遗传性疾病发生的原因,这些疾病包括2A型和2B型多发性内分泌腺瘤(MEN)、家族性甲状腺髓样癌(FMTC)和先天性巨结肠(HSCR)。据报道,一些家族同时发生了MEN 2A/FMTC和HSCR,这些家族中RET基因第609、618或620位密码子的半胱氨酸残基存在突变。在此,我们报告在一个患有甲状腺髓样癌和HSCR的日本家族中检测到一种新的RET突变。在这个家族中鉴定出RET基因第611位半胱氨酸的种系突变,该突变导致氨基酸从半胱氨酸变为丝氨酸。通过对突变型RET蛋白的生物学和生化分析,我们之前预测第611位半胱氨酸以及第609、618和620位半胱氨酸的氨基酸替代可能会促进MEN 2A/FMTC和HSCR的发生。这个临床病例证实了我们对这两种疾病发病机制的推测。